Piotr Tomczak
机构：Poznan University of Medical Sciences, Centrum Medyczne iMed24, Adam Mickiewicz University in Poznań · ORCID：0000-0002-8816-5525
发表论文 202 篇 · 总被引 25479 次 · h-index 42
代表论文
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (2024 · New England Journal of Medicine · 被引 311)
- Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial (2023 · The Lancet · 被引 201)
- Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial (2023 · The Lancet Oncology · 被引 153)
- Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). (2024 · Journal of Clinical Oncology · 被引 35)
- Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma (2023 · The Oncologist · 被引 23)
- First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial (2025 · European Urology · 被引 13)